Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 63.67% | 493.02% | 128.47% | 431.75% | -16.42% |
| Total Depreciation and Amortization | 4.21% | 2.10% | -9.69% | -13.41% | -10.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.38% | 613.98% | -14.89% | -175.10% | -33.84% |
| Change in Net Operating Assets | 46.00% | -621.22% | -4,835.67% | 5,761.66% | 1,161.22% |
| Cash from Operations | 70.26% | -572.28% | -25.25% | 4,812.89% | 4,311.25% |
| Capital Expenditure | -- | 95.79% | 100.00% | 5.56% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.69% | -96.25% | -476.66% | -1,109.48% | 78.94% |
| Cash from Investing | 71.69% | -96.25% | -476.16% | -1,096.24% | 79.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,105.00% | 199.39% | 1,012.00% | -100.00% | -- |
| Repurchase of Common Stock | -565.68% | -274.81% | -70.78% | -8.64% | 49.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -553.04% | -308.49% | -7.53% | -1,043.18% | 50.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.20% | -148.32% | -366.56% | 2,387.22% | 409.57% |